Schedule of Collaborative Revenues Under Collaboration Agreement |
Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands): | | | | | | | | | | | | | | Year Ended December 31, | | 2017 | | 2016 | | 2015 | Royalties accruing to GSK | $ | 12,413 |
| | $ | 4,334 |
| | $ | 1,029 |
|
Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands): | | | | | | | | | | Year Ended December 31, | | 2017 | | 2016 | Milestones achieved | $ | 45,000 |
| | $ | 20,000 |
| Amortization of upfront payments and deferred milestone | 18,531 |
| | 13,284 |
| Royalty revenue | 3,831 |
| | 175 |
| Development cost reimbursements | 4,417 |
| | — |
| Product supply agreement revenue | 6,390 |
| | 1,612 |
| Cost of supplied product | (6,390 | ) | | (1,555 | ) | Royalty payable to GSK on net sales by Ipsen | (1,987 | ) | | (264 | ) | Collaboration revenues under the collaboration agreement with Ipsen | $ | 69,792 |
| | $ | 33,252 |
|
Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands): | | | | | | | | | | | | | | Year Ended December 31, | | 2017 | | 2016 | | 2015 | Collaboration revenues: | | | | | | Royalty revenues on ex-U.S. sales of COTELLIC | $ | 6,398 |
| | $ | 2,827 |
| | $ | 14 |
| U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses | $ | (2,140 | ) | | $ | 8,771 |
| | $ | (16,600 | ) |
Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands): | | | | | | Year Ended December 31, 2017 | Amortization of upfront payment | $ | 10,377 |
| Development cost reimbursements | 4,320 |
| Product supply agreement revenue | 82 |
| Collaboration revenues under the collaboration agreement with Takeda | $ | 14,779 |
|
|